LAUSR

Obstructive Sleep Apnea (OSA) is a highly prevalent respiratory disease. In the subgroup of OSA patients on Positive Airway Pressure (PAP), telemonitoring for CPAP (Continuous Positive Airway Pressure) have emerged as follow-up option to monitor and detect poor compliance to treatment. We aimed to understand whether telemonitoring is an independent factor in the therapeutic adherence of OSAS patients. A retrospective assessment was carried out in patients followed in the Sleep Medicine consultation between March 2019 and June 2022. A total of 312 patients with Resmed® model S10 CPAP devices with residual apnea detection algorithm, mean therapy pressure, and the number of hours of daily use ware included. After placement of the PAP patients were reassessed by consultation at 3, 6, 12, 24 and 36 months of therapy. A total of 312 patients were evaluated, 203 men and 109 women, with a mean daily use of 6 hours and 43 minutes, with a standard deviation of 1 hour and 52 minutes. The residual AHI of averaged 2.58/hour. In June 2022, 30 patients were included at 3 months, 30 at 6 months, 41 at 12 months, 84 at 24 months and 127 at 36 months, with a mean daily use of respectively: 4.29 (median 5.17), 4.33 (median 4.44), 3.52 (median 4.45), 5.05 ( median 5.59) and 4.40 hours (median (5.28), with no statistical significance and adherence being similar from the first trimester, as well as in the divisions of patients per group. This analysis shows that adherence did not decrease over the months of telemonitoring, which may mean that patients felt permanently monitored. The mean Residual AHI was respectively: 4.64, 2.08, 2.33, 2.33 and 2.37/hour, we found that the disease remained controlled and without much variation. We obtained an excellent adaptation to therapy in 262 patients (84%), and 16% (50 patients) abandoned therapy. In patients with a confirmed diagnosis of OSA treated by PAP, telemonitoring has proven to be a helpful tool for a better follow-up and therapeutic adjustment, promoting ideal compliance to therapy, which is effective as early as the first three months.